158 related articles for article (PubMed ID: 36482843)
1. Real-world outcomes of pembrolizumab for platinum-refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit patients.
Ito K; Kita Y; Kobayashi T
Int J Urol; 2023 Sep; 30(9):696-703. PubMed ID: 36482843
[TBL] [Abstract][Full Text] [Related]
2. Editorial comment to real-world outcomes of pembrolizumab for platinum refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit patients.
Goto Y
Int J Urol; 2023 Sep; 30(9):704. PubMed ID: 36482811
[No Abstract] [Full Text] [Related]
3. Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma.
Fukuokaya W; Yanagisawa T; Hashimoto M; Yamamoto S; Koike Y; Imai Y; Iwatani K; Onuma H; Ito K; Urabe F; Tsuzuki S; Kimura S; Miki J; Oyama Y; Abe H; Kimura T
Cancer Immunol Immunother; 2023 Apr; 72(4):841-849. PubMed ID: 36102985
[TBL] [Abstract][Full Text] [Related]
4. Comparative Effectiveness of Immune Checkpoint Inhibitors in Patients with Platinum Refractory Advanced Urothelial Carcinoma.
Swami U; Haaland B; Kessel A; Nussenzveig R; Maughan BL; Esther J; Sirohi D; Pal SK; Grivas P; Agarwal N
J Urol; 2021 Mar; 205(3):709-717. PubMed ID: 33080152
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden.
Srivastava T; Prabhu VS; Li H; Xu R; Zarabi N; Zhong Y; Pellissier JM; Perini RF; de Wit R; Mamtani R
Eur Urol Oncol; 2020 Oct; 3(5):663-670. PubMed ID: 31412001
[TBL] [Abstract][Full Text] [Related]
6. Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinoma.
Uchimoto T; Fukushima T; Komura K; Fukuokaya W; Adachi T; Hashimoto T; Yoshizawa A; Nakamura K; Yano Y; Nishimura K; Nishio K; Nakamori K; Iwatani K; Yamamoto S; Urabe F; Mori K; Yanagisawa T; Tsuduki S; Takahara K; Inamoto T; Miki J; Kimura T; Ohno Y; Shiroki R; Egawa S; Azuma H
BJU Int; 2023 Apr; 131(4):477-485. PubMed ID: 36098556
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status.
Grivas P; Plimack ER; Balar AV; Castellano D; O'Donnell PH; Bellmunt J; Powles T; Hahn NM; de Wit R; Bajorin DF; Ellison MC; Frenkl TL; Godwin JL; Vuky J
Eur Urol Oncol; 2020 Jun; 3(3):351-359. PubMed ID: 32423837
[TBL] [Abstract][Full Text] [Related]
8. Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma.
Koshkin VS; Grivas P
Curr Oncol Rep; 2018 Apr; 20(6):48. PubMed ID: 29644490
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.
Nishiyama H; Yamamoto Y; Sassa N; Nishimura K; Fujimoto K; Fukasawa S; Yokoyama M; Enokida H; Takahashi K; Tanaka Y; Imai K; Shimamoto T; Perini R; Frenkl T; Bajorin D; Bellmunt J
Int J Clin Oncol; 2020 Jan; 25(1):165-174. PubMed ID: 31729625
[TBL] [Abstract][Full Text] [Related]
10. Clinical practice pattern in patients with advanced urothelial cancer who had progressed on pembrolizumab in the pre-enfortumab vedotin era.
Kita Y; Ito K; Sano T; Hashimoto K; Mochizuki T; Shiraishi Y; Araki H; Fujiwara M; Kanamaru S; Takahashi T; Hishiki K; Okada T; Ogawa K; Ito M; Kojima T; Nishiyama N; Matsui Y; Nishiyama H; Kitamura H; Kobayashi T
Int J Urol; 2022 Jul; 29(7):647-655. PubMed ID: 35304776
[TBL] [Abstract][Full Text] [Related]
11. Comparison of pembrolizumab with conventional chemotherapy after first-line platinum-based chemotherapy for advanced urothelial carcinoma in real-world practice: A multicenter retrospective study.
Narita T; Hatakeyama S; Numakura K; Kobayashi M; Muto Y; Saito M; Narita S; Tanaka T; Noro D; Tokui N; Yoneyama T; Hashimoto Y; Habuchi T; Ohyama C
Int J Urol; 2021 Sep; 28(9):899-905. PubMed ID: 34028105
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
Tripathi A; Plimack ER
Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab Combined With Either Docetaxel or Gemcitabine in Patients With Advanced or Metastatic Platinum-Refractory Urothelial Cancer: Results From a Phase I Study.
Parikh M; Pan CX; Beckett LA; Li Y; Robles DA; Aujla PK; Lara PN
Clin Genitourin Cancer; 2018 Dec; 16(6):421-428.e1. PubMed ID: 30166228
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review.
Narayan V; Kahlmeyer A; Dahm P; Skoetz N; Risk MC; Bongiorno C; Patel N; Hwang EC; Jung JH; Gartlehner G; Kunath F
Cochrane Database Syst Rev; 2018 Jul; 7(7):CD012838. PubMed ID: 30036453
[TBL] [Abstract][Full Text] [Related]
15. Update of systemic immunotherapy for advanced urothelial carcinoma.
Gartrell BA; He T; Sharma J; Sonpavde G
Urol Oncol; 2017 Dec; 35(12):678-686. PubMed ID: 29079131
[TBL] [Abstract][Full Text] [Related]
16. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
Balar AV; Castellano D; O'Donnell PH; Grivas P; Vuky J; Powles T; Plimack ER; Hahn NM; de Wit R; Pang L; Savage MJ; Perini RF; Keefe SM; Bajorin D; Bellmunt J
Lancet Oncol; 2017 Nov; 18(11):1483-1492. PubMed ID: 28967485
[TBL] [Abstract][Full Text] [Related]
17. Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study.
Santoni M; Myint ZW; Büttner T; Takeshita H; Okada Y; Lam ET; Gilbert D; Küronya Z; Tural D; Pichler R; Grande E; Crabb SJ; Kemp R; Massari F; Scagliarini S; Iacovelli R; Vau N; Basso U; Maruzzo M; Molina-Cerrillo J; Galli L; Bamias A; De Giorgi U; Zucali PA; Rizzo M; Seront E; Popovic L; Caffo O; Buti S; Kanesvaran R; Kopecky J; Kucharz J; Zeppellini A; Fiala O; Landmesser J; Ansari J; Giannatempo P; Rizzo A; Zabalza IO; Monteiro FSM; Battelli N; Calabrò F; Porta C
Cancer Immunol Immunother; 2023 Sep; 72(9):2961-2970. PubMed ID: 37248424
[TBL] [Abstract][Full Text] [Related]
18. Evaluating Real-World Characteristics of Patients With Advanced Urothelial Carcinoma Eligible for Avelumab Maintenance Therapy: A Multicountry Retrospective Medical Chart Review.
Bellmunt J; Chang J; Pavilack-Kirker M; Cappelleri JC; Costa N; Esterberg E; Kearney M; Hitchens A; Candrilli SD; Ajmera M
Clin Genitourin Cancer; 2023 Aug; 21(4):459-466. PubMed ID: 37149458
[TBL] [Abstract][Full Text] [Related]
19. Clinical Benefit of Pembrolizumab in Advanced Urothelial Cancer Patients in Real-Life Setting: An Efficacy and Safety Monocentric Study.
Dang E; Vallée A; Lepage-Seydoux C; Sejean K; Bonan B; Abraham C; Beuzeboc P; Ratta R
Curr Oncol; 2022 Feb; 29(2):945-955. PubMed ID: 35200579
[TBL] [Abstract][Full Text] [Related]
20. TALASUR trial: a single arm phase II trial assessing efficacy and safety of TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma.
Coquan E; Clarisse B; Lequesne J; Brachet PE; Nevière Z; Meriaux E; Bonnet I; Castera M; Goardon N; Boutrois J; Travers R; Joly F; Grellard JM; Thiery-Vuillemin A
BMC Cancer; 2022 Nov; 22(1):1213. PubMed ID: 36434554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
